C-MER MEDICAL's net profit in 2025 is expected to reach 100 million Hong Kong dollars. Optimizing operations and expanding cross-border business will be the key drivers of growth.

On March 27, C-MER MEDICAL (03309) officially released its annual performance for 2025. During the reporting period, the company achieved operating income of HK$1.947 billion. The operational quality continued to improve, successfully turning losses into profits, with a net profit of HK$100 million for the shareholders, significantly restoring profitability. Leveraging the dividends of the deepening integration policies between Shenzhen and Hong Kong and the continued release of cross-border medical demand, the company's growth model of "mainly focusing on ophthalmology, synergizing with dentistry, and driven by cross-border activities" has been fully implemented, coupled with stable dividend returns, gradually highlighting its investment value. In 2025, C-MER MEDICAL adhered to the strategic layout of "stable foundation in Hong Kong, expansion in the mainland, and seamless cross-border services", continuously optimizing operational efficiency, controlling costs, and driving fundamental performance reversal. With the facilitation of personnel exchanges in the Guangdong-Hong Kong-Macao Greater Bay Area and the normalization of Hong Kong residents seeking medical treatment in the mainland, the company has steadily increased the flow of cross-border patients, continuously optimizing the high-margin business structure of essential eye care treatment, high-end refraction, and dental implantation, driving the simultaneous improvement of overall gross margin and net profit margin. While the company's financial fundamentals continue to improve, it actively rewards shareholders by proposing to distribute a final dividend and a special dividend totaling 3 Hong Kong cents per share, demonstrating strong operational cash flow and sufficient confidence in long-term development. In terms of growth logic, C-MER MEDICAL has formed three major deterministic engines: The first is the deep barriers to entry in the ophthalmology industry, with core specialties such as cataracts, refraction, and retinal diseases having technological and brand advantages, leading to an increase in total treatment volume and average customer spending. The second is the continuous increase in cross-border dental visits becoming the second growth curve, contributing to stable income and profits. The third is the formation of a closed-loop cross-border medical system between Shenzhen and Hong Kong, with continuous policy incentives, high repurchase rates of cross-border patients, strong payment capabilities, supporting long-term steady growth. In the future, the company will continue to deepen its presence in the Greater Bay Area, promote specialization, standardization, and expansion of chains, further increasing market share and operational efficiency. With performance returning to a growth trajectory and the continuous optimization of profit structure, C-MER MEDICAL is entering a new stage of high-quality development, opening up further long-term growth opportunities.